passage-282
abstract
Apaziquone for non-muscle invasive bladder cancer: a critical review.  OBJECTIVE: To describe clinical needs in non-muscle invasive bladder cancer (NMIBC) and review the potential of apaziquone in this respect. METHODS: Epidemiology and clinical practice in NMIBC, as well as new drugs and strategies are reviewed. RESULTS: Bladder cancer is a heterogeneous and frequent disease. Clinical risk factors help in determining additional therapy after initial resection. However, current treatments have clear limitations with regard to efficacy and/or toxicity. New drugs and strategies have been tested recently and are in (pre)clinical use. Intravesical apaziquone (EOquin) is a new drug. It has theoretical advantages for intravesical use, has proven safety and is presently under further clinical evaluation. CONCLUSION: Apaziquone is a promising drug for intravesical use in patients with NMIBC.
entity-282-0
DISEASE
non-muscle invasive bladder cancer
entity-282-1
DISEASE
non-muscle invasive bladder cancer
entity-282-2
DISEASE
NMIBC
entity-282-3
DISEASE
NMIBC
entity-282-4
DISEASE
Bladder cancer
entity-282-5
DISEASE
NMIBC